{
    "title": "113_s1657",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Increasing the Safety of \nPrescription Drug Use Act of 2013''.\n\nSEC. 2. PRESCRIPTION DRUG MONITORING PROGRAM.\n\n    (a) Controlled Substance Monitoring Program.--Section 399O of the \nPublic Health Service Act (42 U.S.C. 243g-3) is amended--\n            (1) in subsection (e), by adding at the end the following:\n            ``(5) The State shall--\n                    ``(A) ensure that the database--\n                            ``(i) is interoperable with the controlled \n                        substance monitoring program of other States \n                        and other Federal agencies and across \n                        appropriate State agencies, including health \n                        agencies, as determined by the Secretary;\n                            ``(ii) is interoperable with electronic \n                        health records and e-prescribing, where \n                        appropriate; and\n                            ``(iii) provides automatic, real-time or \n                        daily information about a patient when a \n                        practitioner (or the designee of a \n                        practitioner, where permitted) requests \n                        information about such patient;\n                    ``(B) require practitioners to use State database \n                information to help determine whether to prescribe or \n                renew a prescription for a controlled substance; and\n                    ``(C) require dispensers, or their designees, where \n                permitted, to enter data required by the Secretary, \n                including the name of the patient, the date, and \n                prescription dose, into the database for a controlled \n                substance.\n            ``(6) Notwithstanding section 543 and any other provision \n        of law, the data required to be entered under paragraph (5)(C) \n        shall include information with respect to methadone that is \n        dispensed to a patient, if applicable.\n            ``(7) The State shall ensure that--\n                    ``(A) any person who receives patient information \n                through the database may disclose and use such \n                information only to carry out the official duties of \n                that person with regard to the patient; and\n                    ``(B) notwithstanding subsection (f)(1)(B), no \n                information kept in accordance with a database \n                developed or maintained through a grant under this \n                section may be used to conduct a criminal investigation \n                or substantiate any criminal charges against a patient \n                or to conduct any investigation of a patient relating \n                to methadone use of the patient.''; and\n            (2) in subsection (n), by striking ``To carry out this \n        section'' and all that follows through the period at the end \n        and inserting ``There are authorized to be appropriated for \n        fiscal years 2014 through 2018 such sums as may be necessary to \n        carry out this section.''.\n    (b) Confidentiality of Records.--Section 543(a) of the Public \nHealth Service Act (42 U.S.C. 290dd-2(a)) is amended by inserting ``or, \nwith respect to methadone, as required under section 399O(e)(6)'' \nbefore the period at the end.\n    (c) Requirements for Federal Health Care Programs.--Health care \npractitioners (as defined in paragraph (7) of section 399O(m) of the \nPublic Health Service Act (42 U.S.C. 280g-3(m))) and dispensers (as \ndefined in paragraph (4) of such section) who participate in or are \nemployed by a Federal health care program or federally funded health \ncare program, including the Indian Health Service, the Department of \nVeterans Affairs, the Department of Defense, the Federal Bureau of \nPrisons, the Medicare program under title XVIII of the Social Security \nAct (42 U.S.C. 1395 et seq.), a State Medicaid plan under title XIX of \nthe Social Security Act (42 U.S.C. 1396 et seq.), the Children's Health \nInsurance Program under title XXI of the Social Security Act (42 U.S.C. \n1397aa et seq.), and Federally qualified health centers, shall use the \ndatabases of the controlled substance monitoring programs under section \n399O of the Public Health Service Act (42 U.S.C. 280g-3), if such \ndatabases are available to the practitioner or dispenser.\n\nSEC. 3. PILOT PROJECT.\n\n    (a) In General.--The Secretary of Health and Human Services \n(referred to in this subsection as the ``Secretary'') shall award \ngrants to one or more States to carry out a 1-year pilot project to \ndevelop a standardized peer review process and methodology to review \nand evaluate prescribing and pharmacy dispensing patterns, through a \nreview of prescription drug monitoring programs (referred to in this \nsection as ``PDMP'') in the States receiving such grants.\n    (b) Methodology.--The recipients of a grant under this section \nshall develop a systematic, standardized methodology to identify and \ninvestigate questionable or inappropriate prescribing and dispensing \npatterns of substances on schedule II or III under section 202 of the \nControlled Substances Act (21 U.S.C. 812). Such peer review methodology \nand prescribing and dispensing patterns shall be shared with the \nappropriate State health profession board.\n    (c) Requirements.--A State receiving a grant under this section \nshall--\n            (1) with respect to controlled substances for which a \n        prescriber is required to have a license issued by the Drug \n        Enforcement Administration in order to prescribe such \n        controlled substances, make the information with respect to \n        such controlled substances from the PDMP available to State \n        regulation and licensing boards; and\n            (2) with respect to any other controlled substances, may \n        make the information with respect to such controlled substances \n        from the PDMP available to State regulation and licensing \n        boards.\n    (d) Subgrantees.--A quality improvement organization with which the \nSecretary has entered into a contract under part B of title XI of the \nSocial Security Act may serve as the subgrantee under this subsection \nto develop peer review processes as described in subsection (a).\n\nSEC. 4. PRESCRIPTION DRUG AND OTHER CONTROLLED SUBSTANCE ABUSE \n              PREVENTION.\n\n    Part P of title III of the Public Health Service Act (42 U.S.C. \n280g) is amended by adding at the end the following:\n\n``SEC. 399V-6. PRESCRIPTION DRUG AND OTHER CONTROLLED SUBSTANCE ABUSE \n              PREVENTION.\n\n    ``(a) Training Grants.--\n            ``(1) In general.--The Secretary shall award 5-year grants \n        to eligible entities to facilitate training in order to \n        increase the capacity of health care providers to conduct \n        patient screening and brief interventions, such as in health \n        care settings to prevent the abuse of prescription drugs and \n        other controlled substances. The grant program under this \n        section may be coordinated with the Screening Brief \n        Intervention and Referral to Treatment grant program of the \n        Substance Abuse and Mental Health Services Administration, or \n        other appropriate program.\n            ``(2) Eligible entities.--In this subsection, the term \n        `eligible entity' includes--\n                    ``(A) States;\n                    ``(B) continuing education entities, such as health \n                profession boards or health accrediting bodies; and\n                    ``(C) other appropriate health or professional \n                education organizations or institutions.\n    ``(b) Federal Health Care Workers.--Health care providers who \nparticipate in or are employed by a Federal health care program, \nincluding the Indian Health Service, the Department of Veterans \nAffairs, the Department of Defense, the Federal Bureau of Prisons, the \nMedicare program under title XVIII of the Social Security Act (42 \nU.S.C. 1395 et seq.), a State Medicaid plan under title XIX of the \nSocial Security Act (42 U.S.C. 1396 et seq.), the State Children's \nHealth Insurance Program under title XXI of the Social Security Act (42 \nU.S.C. 1397aa et seq.), and Federally qualified health centers, shall \nscreen patients for abuse of prescription drugs or other controlled \nsubstances, conduct brief interventions, and provide referrals for \nknown or suspected abuse of prescription drugs or other controlled \nsubstances, as appropriate.\n    ``(c) Expansion of Prescribing Authority.--The Secretary, acting \nthrough the Administrator of the Health Resources and Services \nAdministration, shall award grants to States for the purpose of \nevaluating the prospect of the health professions board of such States \nreviewing and expanding prescribing authorities of providers, such as \nadvance practice nurses and physician's assistants, in order to control \nthe abuse of prescription drugs or other controlled substances with \nrespect to specific drugs and other controlled substances, as \nappropriate.''.\n\nSEC. 5. PRESCRIPTION DRUG ABUSE TRAINING AND SCREENING PROGRAMS.\n\n    (a) Continuing Education Grants.--The Secretary of Health and Human \nServices (referred to in this section as the ``Secretary'') shall award \ngrants to States to develop continuing education criteria and review \nprocesses that allow State health profession boards or State agencies \nto certify appropriate education and training for informed and safe \nprescribing of opioids and other drugs on schedule II and III under \nsection 202 of the Controlled Substances Act (21 U.S.C. 812).\n    (b) Registration With DEA.--A practitioner who registers or renews \na registration under section 303(f) of the Controlled Substances Act \n(21 U.S.C. 823(f)) shall, at the time of registering, certify to the \nAttorney General that such practitioner has completed continuing \nmedical education--\n            (1) in the case of a practitioner registering for the first \n        time, with respect to prescription drug abuse; and\n            (2) in the case of a practitioner renewing a registration, \n        with respect to medical understanding of the proper use of all \n        drugs listed in the schedules under section 202 of the \n        Controlled Substances Act (21 U.S.C. 812).\n    (c) Screening Program.--The Attorney General shall require that a \npractitioner registered under section 303(f) of the Controlled \nSubstances Act (21 U.S.C. 823(f)) conduct patient screening for \npotential drug misuse or abuse before prescribing a drug listed on \nschedule II or III under section 202 of the Controlled Substances Act \n(21 U.S.C. 812), according to standards established by the applicable \nState licensing body.\n\nSEC. 6. FDA REVIEW OF NALOXONE.\n\n    The Secretary of Health and Human Services, acting through the \nCommissioner of Food and Drugs, shall conduct a review of naloxone to \nconsider whether naloxone should cease to be subject to section 503(b) \nof the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)) and be \navailable as a behind-the-counter drug, in order to increase access of \nsuch drug to community-based organizations and street outreach \norganizations.\n\nSEC. 7. PRESCRIPTION DRUG DISPOSAL.\n\n    The Secretary of Health and Human Services shall convene or \ncoordinate with an existing entity an interagency working group to \nencourage States and local governments to increase opportunities for \ndisposal of opiates, such as frequent ``take-back programs'' and fixed \nmedicine disposal sites at law enforcement public buildings, and to \nreduce opportunities for abuse of opiates, such as establishing opioid \ndispensing limits at hospital emergency departments.\n\nSEC. 8. GAO REPORT.\n\n    The Comptroller General of the United States shall review \nprescription drug abuse programs and policies in Federal agencies and \nbest practices with respect to prescription drug abuse programs of the \nStates and, not later than 18 months after the date of enactment of \nthis Act, shall issue a report to Congress on its findings and \nrecommendations on ways to reduce prescription drug abuse."
}